STEMEDICA ENTERS INTO STEM CELL LICENSING AGREEMENT WITH KALBE FARMA
- Hits: 395
Stemedica Asia PTE, LTD, a wholly owned subsidiary of Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced that the Company has entered into a definitive licensing agreement with the Stem Cell and Cancer Institute, a division of PT Kalbe Farma Tbk. (Kalbe). Under the terms of the Agreement Kalbe shall be the exclusive licensor of Stemedica’s ischemic tolerant adult allogeneic mesenchymal and neural stem cells for use in clinical trials in Indonesia, Philippines and Thailand. The Agreement also provides Kalbe with first rights of refusal for additional countries including Singapore, Malaysia, Vietnam, Brunei, Cambodia, Laos and Myanmar. Kalbe’s Stem Cell and Cancer Institute shall be responsible for organizing and funding clinical trials in Southeast Asia.
Headquartered in Central Jakarta, Indonesia, Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with close to US $6 billion in market capitalization as of Q1 2013. Established in 1966, Kalbe has expanded by strategic acquisitions of companies involved in prescription and over-the-counter pharmaceuticals, energy drinks and nutritional products. Kalbe’s Prescription Pharmaceutical Division features a complete product range including the manufacture of generics and licensed drugs. Pharma Metric Labs, a Kalbe company, is an independent Contract Research Organization (CRO) providing global studies in oncology, monoclonal antibodies and stem cells. Kalbe’s packaging and distribution capabilities allow the company to reach over one million outlets with their brands.
Kalbe’s Stem Cell and Cancer Institute was established in 2006 as part of Kalbe’s founder Dr. Boenjamin Setiawan’s belief that stem cells and regenerative medicine represent the future of medicine. According to Dr. Setiawan, “Our scientists and researchers have thoroughly evaluated worldwide stem cell manufacturers. We have chosen to license Stemedica products based upon the quality of their cGMP manufacturing and the unique attributes of their ischemia tolerant stem cells. Their ability to scale production to treat hundreds of thousands of patients from a single tissue donation is in keeping with our objective as a pharmaceutical company is to bring a safe, effective, off-the-shelf solution to millions of people in Southeast Asia suffering from disease.”
Nikolai Tankovich, MD, PhD, President and Chief Medical Officer of Stemedica noted, “We are honored to be associated with a company of Kalbe’s caliber; a company that strictly adheres to the ethical and regulatory guidelines in medicine.”
Addressing the significance of the collaboration, Maynard Howe, PhD, Stemedica’s Vice-Chairman and Chief Executive Officer noted, “Our agreement with Kalbe is in keeping with our corporate strategy of partnering with global and regional pharmaceutical companies that are committed to licensing our multiple stem cell products for use in approved clinical trials. We are extremely pleased to have a strong partner such as Kalbe for Southeast Asia.”
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and myocardial infarct. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.
About PT. Kalbe Farma Tbk.
PT Kalbe Farma Tbk. (“Kalbe”) is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. Kalbe has a broad and strong portfolio of brands in prescription pharmaceuticals (Cefspan, Brainact, Broadced, etc), OTC pharmaceuticals (Woods, Promag, Mixagrip, Komix, etc), ready-to-drink products (Hydro Coco, Extra Joss, Nitros) and nutritional products (Milna, Prenagen, Diabetasol, etc), complemented with a robust distribution arm covering much of the Indonesian archipelago. Since 1991, Kalbe’s shares have been listed on the Indonesia Stock Exchange (IDX: KLBF).